MedX Health unentdeckte Perle ! - 500 Beiträge pro Seite

[Trading_Alert]

http://www.medxhealth.com/



Aktie mit Potential zum Tenbagger. Völlig unterschätzes Unternehmen - enormes Marktpotential. Eine langjährige Partnerschaft mit der ebenfalls börsennotierten INJEX Pharma AG [WKN: A0STYL
ISIN: DE000A0STYL7] (MMB Berlin) eröffnet Meilensteinpotential für beide Unternehmen. MedX Health & INJEX Pharma AG mit deutlichem KursPotential !
Der Markt für medizinische Laser ist ein Milliarden Markt. MedX hat erst im Februar eine Zulassung für ein SKIN CANCER IMAGING SYSTEM erhalten. Ein weitere MEILENSTEIN !


MedX Health ist ein Marktführer in der Entwicklung, Herstellung und Vertrieb von qualitativ hochwertiger Low-Level-Laser-und Lichttherapie-Technologie für den Einsatz in den verschiedensten medizinischen Situationen.




MedX receives Health Canada approval for MoleMate

http://www.medxhealth.com/documents/PR_MoleMate%20HC%20Appro…

2012-02-08 18:16 ET - News Release



Mr. Steve Guillen reports

HEALTH CANADA APPROVES SKIN CANCER IMAGING SYSTEM, MOLEMATE CANADA

[Trading_Alert]

Kursziel Ende des Jahres 2 $ aktuell 0,17 $ ! Bei nur 36 Millionen Aktien ist die aktuelle Börsenbewertung einfach nur witzig. Die 1 $ Marke scheint nach den ganzen News kurzfristig greifbar. Der Markt ist aufgewacht und erkennt das Blockbuster Potential von MedX Health.

Für INJEX Pharma AG ein Geschenk nach dem Handy Sana Deal !





http://ca.hotstocked.com/article/30301/canadian-market-now-o…


by Gediminas Jasionis Feb 10, 2012



Canadian Market Now Open for MedX Health Corp.


MedX Health Corp. (CVE:MDX) (PINK:MDXHF) stock price skyrocketed after the company got an approval to sell their mole examination product in Canada.

MDX stock price hit a new multi-year high at 28 cents per share as it increased 467% over just one session. The trading volume behind the move was 12.9 million, 655 times above the daily average of 19.6 thousand. Naturally, because of this performance the stock was listed among the most actively traded stocks on the Venture Exchange.

The price move was created by simple, yet powerful, news. On February 8, the company announced to have received an approval from Health Canada for their MoleMate product. The news has clearly surprised the market, although the product was already available in Europe, Australia and the US.

molemate.jpgMoleMate is a handheld device used for non-invasive imaging and allows viewing the deeper parts of moles during examinations. The device provides information related to the known types of melanomas and moles in general. It scans 2 mm deep below the surface area.

Following the approval, MoleMate is already available in stock for physicians in Canada, meaning the company can start profiting right away. This is very good news for investors and it wouldn't be surprising to see the share price run further up as the news spreads.

[Trading_Alert]

Die langjährigen Geschäftsbeziehungen von Andy Rösch (Vorstand der INJEX Pharma AG) zur MedX Health werden der INJEX Aktie Auftrieb verleihen.

MedX Health hat das Zeug zum Tenbagger !

ECG Phone Transaction: MedX will issue 27,000,000 common shares at $0.10 to Medical
Marketing Berlin (MMB) as per a signed Letter of Intent (LOI) for a 5 year, renewable, exclusive
North American rights agreement to the H’andy sana 211 with ECG capabilities. MMB is a
corporation controlled by Mr. Andy Rösch, a director of MedX. With the approval of this transaction
by the shareholders, Mr. Rösch will become the largest single MedX shareholder, with 30.34% of the
outstanding shares of MedX.
Private Financing: MedX will issue 20,000,000 common shares at $0.10 to raise $2,000,000. The
completion of the exclusive marketing rights agreement for the ECG Phone transaction is dependent
on raising $2,000,000, because $1,000,000 of the new funding is needed to further develop the
software and hardware for the H’andy sana for the North American cellular systems.


http://www.medxhealth.com/documents/PR_Update_on_ReStructuin…" target="_blank" rel="nofollow ugc noopener">
http://www.medxhealth.com/documents/PR_Update_on_ReStructuin…

Press Release
Page 1 of 3
For Immediate Release
MedX Health Corporation Updates
Shareholders Meeting Date and Re-Structuring Plans
Shares for debt and a private placement
to support launch of new telemedicine product the
H’andy sana 211 cell phone with integrated ECG capability
Mississauga, ON – August 13, 2010 – MedX Health Corp., (TSXV.MDX) a global leader in drug
free, non-invasive low level laser and light therapy for tissue repair and pain relief today provided
additional information to its previously announced plans to re-structure the company through the use
of shares to retire debt, acquire key technologies and raise cash to support the existing and newly
acquired products.
“We are using our shares to re-structure the company financially by reducing the overall debt and
raising needed capital to grow our marketing programs, as well as provide us with a key new
technology, the H’andy sana 211 with ECG capabilities, that will allow us to have a strategic entry
into to the large and rapidly growing telemedicine market,” said Steve Guillen, president & CEO of
MedX.
The following key programs involve the use of common shares issued at $0.10 per share, and are all
subject to TSX approval:
Shares for Debt: MedX will issue 13,447,539 common shares at $0.10 to settle debts to management,
directors, and consultants. Of the 13,447,539 shares, 7,779,232 will be issued to management and
directors for salary and director’s fees that have not been paid, and these shares will require approval
by the majority of the disinterested shareholders at the upcoming AGM, now scheduled for September
30th, 2010.
ECG Phone Transaction: MedX will issue 27,000,000 common shares at $0.10 to Medical
Marketing Berlin (MMB) as per a signed Letter of Intent (LOI) for a 5 year, renewable, exclusive
North American rights agreement to the H’andy sana 211 with ECG capabilities. MMB is a
corporation controlled by Mr. Andy Rösch, a director of MedX. With the approval of this transaction
by the shareholders, Mr. Rösch will become the largest single MedX shareholder, with 30.34% of the
outstanding shares of MedX.
Private Financing: MedX will issue 20,000,000 common shares at $0.10 to raise $2,000,000. The
completion of the exclusive marketing rights agreement for the ECG Phone transaction is dependent
on raising $2,000,000, because $1,000,000 of the new funding is needed to further develop the
software and hardware for the H’andy sana for the North American cellular systems. The remaining
proceeds from the financing will be used to expand MedX’s distribution network; support its
Press Release
Page 2 of 3
marketing programs; continue development of new dental, rehabilitation and wound care products, and
for working capital purposes.
Overall Value of Transactions to Shareholders
Currently, MedX has 28,551,527 shares outstanding and the combined use of shares for the
transactions in this press release would increase the number of shares to 88,999,067. The value
provided to MedX via these shares would be to 1. rapidly improve the financial outlook by reducing
overall debt, 2. increase operating funds, and 3. establish a new product line (telemedicine ECG
phone) that promises to rapidly increase revenues in 2011.
The H’andy sana is already being successfully marketed in other world markets, including the Middle
East. The device has been recently test marketed in Indonesia (population: approx. 5 million) and
generated several million dollars in revenues in a short period of time. By comparison, there are
approximately 344 million people in North America, and therefore the potential market for the H’andy
sana 211 is very large. Within the North American market there is no cellular phone commercially
available with all the features of the H’andy sana with ECG capabilities. Additionally, the ECG phone
is complementary to MedX’s wound care product line featuring PhotoBandage™ and WoundSmart™,
which facilitate treatment and are used to enable remote monitoring of health and medical-related
information.
More About H’andy sana 211
A comparison study demonstrated that the 1-lead ECG via the H’andy sana produced identical results
with the corresponding leads of a standard 12-lead ECG record. Both ECG records were tested in
parallel under clinical conditions. Following the study, Dr. Hans Lehmkuhl, chief cardiologist at the
German Heart Centre in Berlin, Germany stated that he was “impressed and satisfied with the quality
of the ECG recordings using the H’andy sana phone.”
The H’andy sana 211 has a 2.8 inch full touch screen and full-fledged mobile phone capabilities,
including a multimedia suite, internet browser, calendar, built-in camera with screen viewfinder and
dedicated menus. Additionally, it offers a “health suite” of services to store data like blood pressure,
cholesterol, blood glucose, a drug reminder and ECG monitoring. The user only needs to press two
fingers on the phone’s edges for 30 seconds for the phone to pick up an ECG reading.
The H’andy sana 211 can enable patients to monitor their health situation on their own, which
facilitates their work and leisure activities.
Details of these proposed transactions will be included in MedX’s management information circular to
be issued September 10th, 2010.
About MedX Health Corp.
MedX is a leading North American developer and manufacturer of low level laser and light medical
devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical
settings including dental, rehabilitation and wound care. MedX is the world’s only company focusing
Press Release
Page 3 of 3
on developing and delivering a broad cross-section of technologies and products involved in healing
using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free
healing nature of light to people seeking relief from pain and other physical ailments.
MedX’s strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic
manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as
well as developing and commercializing advanced products in the dental and wound-care markets that
will position the company to increase revenue. In addition, MedX plans to accelerate the development
of a new product aimed at the rapidly-growing wound care market: its “Photobandage™”, a bandage
technology that allows a wound to be bathed in light, designed to enhance the healing process. The
Company intends to license this new technology to one or more major wound care companies for
further development of marketing and sales.
Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an
ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX
Health Corp. and its products visit www.medxhealth.com
Contacts:
Investors:
Steve Guillen
President and Chief Executive Officer
MedX Health Corp.
Phone: [phone]
[e-mail]
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities
legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives,
performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information
can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is
expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or
"believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would",
"might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown
risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of
MedX to be materially different from those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of
products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does
not undertake to update any forward-looking information, except in accordance with applicable securities laws.

[Trading_Alert]

MedX to review MoleMate transition on March 13

2012-03-05 09:48 ET - News Release

Mr. Steve Guillen reports

SKIN CANCER IMAGING WITH MOLEMATE ACCELERATES NEW REVENUE GROWTH STRATEGY VIA ENTRY INTO MULTIPLE HUNDRED MILLION DOLLAR MARKETS AND ON-LINE SERVICES

MedX Health Corp.'s annual shareholders meeting will be held on March 13, 2012, at 4 p.m. at the National Club in Toronto, where the president and chief executive officer, Steve Guillen, will review how MoleMate has accelerated the transition into new markets, including on-line services.

At the upcoming meeting of shareholders, Mr. Guillen will expand and update upon the following regarding MoleMate:

Transition to a technology platform company;

On-line imaging services utilizing 'cloud' technology;

Acceleration of new market entries: skin cancer, burns, wound care;

Addition of Mole Mapping in 2012;

Broad worldwide patent portfolio;

Strong sales in Q4 2011, led by MoleMate; best quarter in over three (3) years;

Immediate availability in Canada, the US, and other locations around the world.

"We are fundamentally changing from simply a medical device company to a technology platform company, with broad worldwide patents, and positioned to enter multiple hundred million dollar markets where knowing what is just under the skin is critical for the quality of care of the patient," says Steve Guillen, President and CEO, and "by offering a web based solution, via 'cloud' technology, we can lower the initial cost to physicians, as physicians pay monthly service fees, creating an on-going revenue stream for MedX from each device sold."

Skin Cancer Imaging - First Target

The combined markets in Europe, Canada, Australia, and the US is worth over $200 Million in net device sales (Zach's Equity Research), and the opportunity via 'cloud' technology for recurring revenue could be worth millions of dollars every year in this emerging market.

Burns Assessment Imaging, Diabetic Foot Ulcer Imaging - Second Target The worldwide advanced wound care market (burns, diabetic foot ulcers and bed sores) is estimated at $5 Billion (Global Industry Analysts, Inc.) and the market potential using the MedX platform technology may be worth hundreds of millions of dollars.

About MoleMate Imaging and Skin Cancer

MoleMate recently received approval from Health Canada, and is immediately available and in stock for all Canadian physicians, joining their colleagues in Europe, the UK, Australia, and the US, who have been utilizing this new pain-free, non-invasive imaging system to 'See More', approximately 2mm below the surface of suspicious moles, and provide additional information and images related to every mole and all types of melanomas and non-melanomas.

MoleMate uses a patented device and technology that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. Physicians interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com.

"Among the sophisticated equipment used by University of California Irvine Melanoma Center physicians is a SIMSYS-MoleMate SIAscope, one of the most advanced melanoma imaging systems in the world. For patients with many moles, this computer imaging can make a big difference, it decreases the number of biopsies needed, so they won't look like a pincushion."

- Dr. James G. Jakowatz, surgical oncologist and UC Irvine Melanoma Center director

- Dr. Janellen Smith, UC Irvine dermatologist and co-director of the Pigmented Lesion Program, UC Irvine

MoleMate and the more robust system, SIMSYS, are both sold with a specially designed training CD. SIMSYS allows image capture and storage as well as special features that can be used in visualizing and comparing moles. SIMSYS will include "mole mapping" software early in 2012. Mole Mapping is a technique that physicians use on certain patients with 50-100 or more moles where the entire surface of the patient's skin is photographed to observe changes over time and then suspicious moles can be monitored more closely or, if necessary, removed.

MoleMate is easy to incorporate into exams, and is easy for physicians to learn how to use via the 60-90 minute training CD, as documented in a study with general practitioners, who significantly improved their ability to more accurately identify suspicious moles and lesion.

Learn More

The website www.simsys-molemate.com contains additional information on MoleMate and SIMSYS, including information on the technology behind these products, as well as product demos, and information on how other physicians have integrated the skin cancer imaging system into their practice.

MoleMate and SIMSYS will also be presented at the American Academy of Dermatology's 70th Annual Meeting, March 16-20, 2012, in San Diego, California, the world's largest, most comprehensive dermatologic educational event. "See More," with MoleMate and SIMSYS at booth #1361.

We seek Safe Harbor.

[ikarusfly]

bin jetzt mal mit einer posi dabei

[ikarusfly]

jahreshoch liegt bei 0,25 cd

http://www.comdirect.de/inf/aktien/detail/chart.html?timeSpa…


wenn wir die überwinden

[ikarusfly]

bei den holzfällern null umsatz

[hasi22]

jemand pusht,
Insider verkaufen dauernd 8ung !

[Trading_Alert]

es geht ab - endlich!!!!!!!

http://www.wallstreet-online.de/diskussion/1179096-1-10/medx…

[Trading_Alert]

Medx Health startet .................... !




Zur Erinnerung:

http://www.munknee.com/2012/05/this-skin-cancer-detection-de…

This Skin Cancer Detection Device Could Be a Great Investment in Your Health – and Your Wealth


http://www.reuters.com/assets/sdPrint?aid=2403340&ticker=MDX…

MedX Health Corp. Announces FDA Approval For MoleMate

Medx Health wird gerade gewaltig von den canadischen Investoren entdeckt. Kein Wunder bei dem Newsflow. Eine offizielle News direkt von Medx dürfte nicht mehr lange auf sich warten lassen - doch dann steht die Aktie bei 0,20 $ !

http://www.consumeraffairs.com/news/major-products-and-inven…

The Molemate

Almost every year, scientists and researchers announce a new finding or medical breakthrough that has a huge impact on all of us, and so far there’s been a lot of talk about a skin cancer-detecting device called the MoleMate Skin Imaging System, which allows dermatologists to test for melanoma by just running the device along the skin, instead of doing an invasive procedure like a biopsy.

PhotoThe inventor of the handheld device, Symon Cotton, says physicians will be able to read the machine's light waves to detect melanoma without having to remove a portion of the skin.

The MoleMate “operates by using wave lengths of light that interact with different cells in different ways,” said Cotton in an informational video about the device. “Because we know how they interact with these cells we can identify what’s in the skin without having to do a biopsy, i.e. cut a piece of the skin out.”

The company also says the MoleMate is extremely easy to use, as one pretty much just has to hold the oblong device to a patient’s skin.

What’s also terrific about the device is that physicians will be able to learn how to use it in just a couple of hours. It’s also said the device will be able to detect melanoma at earlier stages and provide more accurate readings.

Although there hasn’t been an exact release date of the Molemate, it has already been approved by the FDA and is rumored to hit U.S. doctor offices by this year. Hopefully by 2014 it will be a device commonly used by dermatologists.

[Trading_Alert]

Börsenbewertung lächerliche 1,7 Mio €. Da dürfte klar sein wo die Reise hingeht. Marktpotential für Medx Health Produkte mehrere 50 Mio $ ! 1. Kursziel dürfte im Bereich 0,50 $ liegen -aktuell 0,065$.
Bei Übernahme Spekulationen oder ÜbernahmeNewsflow dürfte 1 $ / Aktie realistisch sein.

The Company presently has 36,341,513 common shares issued and outstanding.

About MedX Health Corp. MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX Health acquired the worldwide assets of MoleMate™ in June, 2011. For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com. About MoleMate™ Imaging and Skin Cancer MoleMate™ recently received approval from Health Canada, and is immediately available and in stock for all Canadian physicians, joining their colleagues in Europe, the UK, Australia, and the US, who have been utilizing this new pain-free, non-invasive imaging system to 'See More', approximately 2mm below the surface of suspicious moles, and provide additional information and images related to every mole and all types of melanomas and non-melanomas. MoleMate™ uses a patented device and technology that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. Physicians interested in learning more should contact MedX Health Corp. at www.simsys-molemate.com.

[Trading_Alert]

http://www.modernhealthconsulting.com/2013/01/25/molemate/

January 25, 2013

The FDA approved MoleMate Skin Imaging System is a significant advance in the early detection of potentially life threatening moles and lesions.

Physicians have also found the hand-held device easy to learn and use, and that it rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion.

Now, for the first time, physicians can more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way. Experts also believe it may reduce the need for time consuming and expensive biopsies

[Trading_Alert]

BIG DEAL voraus Procter & Gamble und Unilever werden den Trend nicht verpassen wollen ..............

Major products and inventions consumers should watch for in 2013

Although there hasn’t been an exact release date of the Molemate, it has already been approved by the FDA and is rumored to hit U.S. doctor offices by this year. Hopefully by 2014 it will be a device commonly used by dermatologists.

[Trading_Alert]

Assisted Living Concepts Inc. ist ein profitables Unternehmen mit fast 250 Millionen $ Börsenwert - was auch Dividende zahlt. Die sind in MedX Health investiert.

MedX Health hat gegenwärtig einen Börsenwert von nur 1,6 Mio € - dagegen stehen die guten News - das MultimillionenPotential der Produkte ect. !

Allein der Markt für MoleMate wird von Brancheninsidern auf mehrere hunderte Millionen Dollar geschätzt. Namhafte Milliardenkonzerne wie Procter & Gamble oder Unilever werden im gleichen Atemzug mit MedX genannt.

Die MedX Phototherapy ist ein weiteres Schwergewicht im Produktportfolio der MedX Health Corp. ! Ein jeder der sich mal 1, 2 Stunden in das Unternehmen einarbeitet - wird das signifikante Marktpotential erkennen.
Daraus resultierend kann man ohne Übertreibung eine Kursverfünffachung als gerechtfertigt sehen.

Bei derzeitigen Kurs von nur 0,06 $ entspreche die avisierte verfünffachung ca. 0,30 $ ! Der Börsenwert würde trotz der Kurssteigerung nur ca. 8,5 Mio € betragen - ein Witz !

Fair bewertet wäre die Aktie vorerst zwischen 1,20 - 1,50 $

http://www.medxhealth.com/healing.html

Under Mr. Guillen’s leadership MedX began to explore other markets for their light products and acquired the Canadian rights to the RJ Laser line of products, which offered advances and features beyond the existing MedX product line.  New markets were added including veterinary, auricular acupuncture, and dermatology.  In early 2008, MedX Health also began to establish an international network of distributors and obtained the CE Mark for all of its products, opening the door to sales in the European Union.



In 2011, MedX Health announced the acquisition of the worldwide assets (Trademarks, IP, existing contracts, etc.) of an innovative skin imaging system called MoleMate™.  MoleMate and its related technologies are FDA approved and CE Marked, and are currently being sold in Australia, New Zealand, Poland, the United Kingdom, and the US.  MedX Health has licensed the use of a version of this technology for skin assessment to Proctor and Gamble for use in pharmacy and cosmetic point-of-sale counters to demonstrate to consumers the condition of their skin before and after the use of P&G skin products.  In June of 2011, MedX began the US launch of MoleMate with an initial national team of 40 sales representatives calling on physicians. MoleMate and its related technologies are used by physicians to help gather extra information about their patient’s suspicious moles and lesions, by imaging pigment, collagen, and blood directly under the mole or lesions.  For the first time, physicians will get clear, color images of these components via this ‘optical biopsy’, helping physicians and patients to come to a more informed decision about diagnosis and removal.

In addition to our core business, ALC holds share investments in MedX Health Corporation, a Canadian publicly traded corporation, and cash or other investments held by
Pearson Indemnity Company Ltd. ("Pearson"), our wholly-owned consolidated
Bermuda based captive insurance company formed primarily to provide self-insured
general and professional liability coverage.

[Trading_Alert]

große Käufer die wissen anscheinend schon mehr! Da ist eine dicke News im Anmarsch wenn man sich die Umsätze anschaut.
Damals gab es einen 300 % Sprung bei MEDX mal sehen obs diesmal die Übernahme wird. Richtig spannend !

[Trading_Alert]

News im Sektor !

Verisante Technology, Inc. Announces First Sales of Aura, a Revolutionary Medical Device for the Detection of Skin Cancer

2013-01-30 10:36 ET - News Release

Verisante 39 Millionen CAD $ Börsenwert

MedX Healt Corp. lächerliche 1,8 Millionen CAD $ - MedX Health bei Übernahme mind. 1 $ / Aktie



http://investmentunderground.com/5904/featured/verisante-tec…





New Skin Cancer Detection Devices

In a very short amount of time, companies including Verisante (VRSEF) have developed devices that use raman spectroscopy to determine the presence of skin cancer. Verisante recently renewed its partnership with the BC Cancer Agency to continue performing research and testing on its skin cancer detection device, the Verisante Aura. This means the company will continue to invest revenue and time into perfecting the device.

In addition to detecting skin cancer, the company has another device, the Verisante Core, which aids in the detection of lung, cervical, and colon cancer.

Other companies trying to prevent the spread of skin cancer through the use of early detection devices include MELA Sciences (MELA) and MedX Health Corporation (MDX). MELA Sciences, which received both EU and FDA approval for its detection device MelaFind, was designed to detect melanoma in patients.

MedX Health Corporation, a company based in Canada, received approval to sell its skin cancer detection device, MoleMate in Canada at the beginning of this year.

As more and more companies develop skin cancer and other cancer detection devices, technologies like raman spectroscopy will become even more advanced.

Skin Cancer Detection Device Market

A niche market within the skin cancer prevention and treatment market, the skin cancer detection market has the potential to bring in steady profits for investors. Marketed mostly to dermatologists, these devices may also be used by general practitioners and clinicians in remote areas with few skin cancer specialists. Portable and easy to use, these devices have the ability to help save countless lives through early detection. Since most forms of skin cancer are preventable and treatable, the number of fatalities due to skin cancer should decline steadily once these devices become accepted and used in more and more areas.

Investors looking for a safe, long-term investment should consider this market. According to the American Academy of Dermatology, an estimated 1 in 50 people in the U.S. will be diagnosed with melanoma each year. This means the need for these types of devices will continue to increase.

Skin Cancer Testing

In addition to increased occurrences of skin cancer, testing for cancer has grown over the years. By 2017, cancer testing revenues will reach about $11.46 billion. With a need for accuracy and ease of testing, more and more physicians and dermatologists will require top-notch skin cancer detection devices. For investors, this could prove very profitable for a very long period of time.

The market potential for skin cancer testing could move beyond the medical office. Home devices may eventually help people diagnose the presence of skin cancer without physician assistance. This could open up a whole new market for investors as well as manufacturers and product developers. And while home testing devices may be a few years away, investors should consider how these devices will evolve in the future.

Since skin cancer, if found early, may be treated under a physician’s care, devices like these should only become more popular over time. Treating skin cancer early not only saves lives, but also cuts medical costs for patients and insurance companies. This alone should help these detection devices find a solid place in the prevention and treatment of skin cancer.

[Trading_Alert]

400,000 Aktien gehandelt 0,06 $ TH die letzte News brachte 500 % intraday auf über 0,31 $ !

Aktuell 0,06 $ und es riecht nach einer dicken guten News

[Trading_Alert]

Übernahme ? Von der Zeit her könnte das passen dazu die hohen Umsätze in Canada ...........



"and identify potential acquisition, divestiture or merger opportunities"



MedX Health hires Byron as strategic adviser 2012-12-05 15:35 ET - News Release Mr. Louie Canitano reports



MEDX HEALTH CORP. ENTERS INTO ADVISORY AGREEMENT WITH BYRON CAPITAL MARKETS MedX Health Corp. (MDX) has entered into an advisory agreement with Byron Capital Markets Ltd. Byron will, over a two-month period commencing on the date of signature of the agreement, facilitate MDX's access to capital markets, and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors and assist MDX in structuring future transactions. MDX will pay Byron a total fee of $200,000, payable as to $100,000 in cash and $100,000 in common shares of the corporation. The issue price of the shares will be calculated pursuant to the policies of the TSX Venture Exchange, and will be subject to all relevant regulatory and other consents and approvals. We seek Safe Harbor.

[Trading_Alert]

verisante 40 Mio $ cs. medx 1,8 Mio $ = 20fache!
Merger oder Investornews dürfte also die nächsten Tage kommen. medx 1$ ?
es tut sich was ........................

[Trading_Alert]

sehr verdächtig dicke Käufer in canada. seit tagen wird sich still und heimlich eingekauft. das riecht nach News. die letzte News brachte intraday über 400 %
schöne einstiegschance bei der niedrigen mcap. BIG NEWS - BIG DEAL !
Über 0,10 $ gehts richtig ab oder bei Übernahme News außerhalb Handel Eröffnung zw. 1 $ - 3 $ möglich !?
Hammer Käufe in den letzten Tagen.

[Zwergmann]

0,07$ Jahreshoch mhhhh jemand dabei? Schon ein interessantes Teil. Im Moment kann man ja noch günstig einsteigen was aber bei good News vor oder nachbörslich ? Dann steht die Bude gleich bei 0,30$. Frankfurt auch regelmäßig Umsätze und Kanada steigt stetig. Hot das Teil denn über 0,08 $ sogar Ausbruch.

[Ad.Hoc]

Interessant

Was ist dran an dem Gerücht das Carl Zeiss an einer Übernahme von MedX Health (WKN: A0YJHF und Canada: MDX) interessiert ist? Wäre ein cleverer Schachzug. MedX ist spottbillig und das bei einem prall gefüllten Produktportfolio.
Irgendwas ist bei MedX Health im Busche.

"and identify potential acquisition, divestiture or merger opportunities"



MEDX HEALTH CORP. ENTERS INTO ADVISORY AGREEMENT WITH BYRON CAPITAL MARKETS MedX Health Corp. (MDX) has entered into an advisory agreement with Byron Capital Markets Ltd. Byron will, over a two-month period commencing on the date of signature of the agreement, facilitate MDX's access to capital markets, and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors and assist MDX in structuring future transactions.


MedX Health Corp. develops, manufactures, and distributes phototherapy devices. Its products comprise MedX phototherapy devices, MedX rehab console systems, MedX rehab handheld lasers, MedX SLD clusters, MedX rehab portable lasers, MedX dental console systems, MedX Oralase (dental) portable lasers, MedXHOME systems, MedX acupuncture console laser systems, and MedX acupuncture portable lasers. The company also provides MoleMate, a non-invasive melanoma screening device early detection of skin cancer. Its products are used by practitioners in clinics, academic facilities, and hospitals as well as by professional athletes and sports teams for the treatment of arthritis, strains, sprains, carpal tunnel syndrome, dental pain, and tissue repair. The company sells its products to medical equipment dealers primarily in Canada, the United States, Europe, and Asia. MedX Health Corp. was incorporated in 1999 and is headquartered in Mississauga, Canada.
Detailed MDX:CN Company Description...
www.medxhealth.com
Founded in 1999

[Ad.Hoc]

http://coldlasersupplies.com/medx-laser-health-systems
http://www.medxhealth.eu/healing.html

[Trading_Alert]

Entweder Übernahme oder Investor heute fast 4 Millionen Aktien in Canada. Rekord Umsätze. Die
 NEUBEWERTUNG medx Health nun endlich Richtung 1$  diese niedrige  BörsenBewertung von 2, 5 Mio ist alles andere fair. Schaut euch EKG an dort wurde eine NEUBEWERTUNG eingepreist. 500 % 4 Tage Börsenwert Cardiocomm  40 millionen. Medx Neubewertung startet nun endlich. Ziel 1 $

Zitat von Trading_Alert: Kursziel Ende des Jahres 2 $ aktuell 0,17 $ ! Bei nur 36 Millionen Aktien ist die aktuelle Börsenbewertung einfach nur witzig. Die 1 $ Marke scheint nach den ganzen News kurzfristig greifbar. Der Markt ist aufgewacht und erkennt das Blockbuster Potential von MedX Health.

Für INJEX Pharma AG ein Geschenk nach dem Handy Sana Deal !





http://ca.hotstocked.com/article/30301/canadian-market-now-o…


by Gediminas Jasionis Feb 10, 2012



Canadian Market Now Open for MedX Health Corp.


MedX Health Corp. (CVE:MDX) (PINK:MDXHF) stock price skyrocketed after the company got an approval to sell their mole examination product in Canada.

MDX stock price hit a new multi-year high at 28 cents per share as it increased 467% over just one session. The trading volume behind the move was 12.9 million, 655 times above the daily average of 19.6 thousand. Naturally, because of this performance the stock was listed among the most actively traded stocks on the Venture Exchange.

The price move was created by simple, yet powerful, news. On February 8, the company announced to have received an approval from Health Canada for their MoleMate product. The news has clearly surprised the market, although the product was already available in Europe, Australia and the US.

molemate.jpgMoleMate is a handheld device used for non-invasive imaging and allows viewing the deeper parts of moles during examinations. The device provides information related to the known types of melanomas and moles in general. It scans 2 mm deep below the surface area.

Following the approval, MoleMate is already available in stock for physicians in Canada, meaning the company can start profiting right away. This is very good news for investors and it wouldn't be surprising to see the share price run further up as the news spreads.

[butcherfriend]

Und WO schläft mal wieder

[Gesprengt]

wird unsere medx übernommen ?
BC Technical Acquires MEDX
http://www.prnewswire.com/news-releases/bc-technical-acquire…" target="_blank" rel="nofollow ugc noopener">
http://www.prnewswire.com/news-releases/bc-technical-acquire…